Connor, Clark & Lunn Investment Management Ltd. Actinium Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ATNM
# of Institutions
70Shares Held
7.94MCall Options Held
59.6KPut Options Held
4.8K-
Black Rock Inc. New York, NY1.88MShares$2.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$2.51 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$1.07 Million0.0% of portfolio
-
State Street Corp Boston, MA621KShares$962,6660.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$773,8530.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $39M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...